WAVE Life Sciences (WVE) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 5, 2021 7:30 AM EDTDosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD first oligonucleotide using PN backbone chemistry modifications in clinical study
Recruitment ongoing for clinical trials in HD and DMD
Generating clinical data in multiple trials through 2022 to enable decision making
Leading endogenous ADAR editing capability demonstrated restoration of functional AAT protein in vivo; new data at Wave Research Day September 28
Wave to host investor conference call and webcast at 8:30 a.m. ET today
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq:... More
